Nectar Lifesciences Limited reports Rs 26.725 crore investment loss

Nectar Lifesciences Limited recorded a Rs 26.725 crore loss on mutual fund, exchange-traded fund (ETF) and equity investments for the half year ended September 30, 2026. The company said market volatility, prevailing market conditions and geopolitical developments reduced investment values, and Rs 25.1329 crore of the loss had already arisen by June 30, 2026.

What caused Nectar Lifesciences' Rs 26.725 crore investment loss?

Nectar Lifesciences said the Rs 26.725 crore loss followed Board-approved deployment of certain surplus funds in mutual funds, ETFs and equity instruments during the year. The company attributed the half-year loss to September 30, 2026 to volatility in financial markets arising from prevailing market conditions and geopolitical developments.

The company recognised the amount in its Statement of Profit and Loss under Indian Accounting Standard (Ind AS) 109, Financial Instruments. Its cash-flow statement labels the Rs 26.725 crore item as a loss or profit on sale and restatement of investments, but the November 14, 2026 filing does not provide a security-level portfolio, realised-versus-unrealised split, or individual values for the funds, ETFs and shares.

The disclosed cumulative figures show that Rs 25.1329 crore of the loss had been incurred up to June 30, 2026. The difference indicates a further Rs 1.5921 crore loss in the quarter ended September 30, 2026, meaning the September-quarter addition was lower than the loss accumulated in the preceding quarter; the filing does not explain changes in portfolio composition or market movements between the quarters.

How much investment trading did Nectar Lifesciences report?

Nectar Lifesciences purchased Rs 879.8934 crore of investments and sold Rs 810.6265 crore during the half year ended September 30, 2026, according to both its standalone and consolidated cash-flow statements. These gross investment flows were substantially larger than the Rs 26.725 crore loss recognised in the same six-month period.

Purchases exceeded sales by Rs 69.2669 crore before valuation changes, interest receipts and other investing cash flows. Consolidated current investments stood at Rs 55.5126 crore on September 30, 2026, compared with Rs 12.9708 crore on March 31, 2026, an increase of Rs 42.5418 crore. Cash-flow purchases and sales are transaction flows, whereas the current-investment balance is a point-in-time figure, so the two measures are not directly interchangeable.

Nectar Lifesciences reported consolidated net cash used in investing activities of Rs 46.7716 crore for the half year ended September 30, 2026, compared with Rs 8.2315 crore in the restated comparable period a year earlier. The current-period investing movements included Rs 22.3325 crore of proceeds from assets held for sale and Rs 1.2089 crore of fixed-asset purchases alongside the investment purchases and sales.

How did the investment loss affect Nectar Lifesciences' results?

Nectar Lifesciences reported a consolidated loss before tax from continuing operations of Rs 17.3475 crore for the half year ended September 30, 2026, against a profit before tax of Rs 60.01 lakh in the restated half year ended September 30, 2025. The Rs 26.725 crore investment loss exceeded the latest half-year pre-tax loss from continuing operations, although other income, expenses and taxes also affected the reported outcome.

The company posted a consolidated loss after tax from continuing operations of Rs 12.1551 crore, compared with a profit of Rs 39.04 lakh in the restated prior-year half year. Including discontinued operations, total consolidated loss after tax was Rs 12.6737 crore in the latest half year, versus Rs 239.2365 crore in the comparative period.

The quarterly pattern was different within the latest half year. Nectar Lifesciences recorded a consolidated profit before tax from continuing operations of Rs 7.272 crore in the quarter ended September 30, 2026, after a loss before tax of Rs 24.6195 crore in the quarter ended June 30, 2026. While the filing does not give a separate September-quarter investment-loss figure, its cumulative disclosures indicate the Rs 1.5921 crore addition calculated from the half-year and June-quarter amounts.

What liquidity did Nectar Lifesciences report after investment activity?

Nectar Lifesciences reported consolidated cash and cash equivalents of Rs 115.5486 crore at September 30, 2026, up from Rs 112.1348 crore at March 31, 2026. Consolidated net cash from operating activities was Rs 51.2587 crore in the half year, while the displayed consolidated balance-sheet lines showed no current or non-current borrowings at September 30, 2026.

Management said that the sale of a substantial part of its existing operations in the previous financial year had generated significant liquidity and that all debts had been discharged. The Board said Nectar Lifesciences had adequate cash and liquid resources to meet obligations and prepared the September 30, 2026 financial results on a going-concern basis; this was the Board's assessment rather than a forecast of investment values.

Total consolidated current assets were Rs 235.2935 crore at September 30, 2026, down from Rs 252.9683 crore at March 31, 2026. This reduction occurred despite the Rs 42.5418 crore rise in current investments and a Rs 3.4138 crore increase in cash and cash equivalents, indicating lower balances in other current-asset categories over the six months.

What plans and asset sales has Nectar Lifesciences disclosed?

Nectar Lifesciences said it amended its object clause to undertake real-estate activities and is evaluating projects under that revised business framework. It acquired Avensis Exports Private Limited as a wholly owned subsidiary in furtherance of this objective, while its other wholly owned subsidiary, Neclife PT, Unipessoal LDA, remained inoperative during the period ended September 30, 2026.

The company is also evaluating monetisation of non-core assets. It said part of its vacant land near Garhshankar, Punjab, had been sold in the current quarter and expected the balance to be sold by the end of the financial year. Separately, Nectar Lifesciences entered into a Business Transfer Agreement dated December 20, 2025, to sell its Empty Hard Gelatin Capsule business for Rs 19.90 crore, subject to working-capital adjustments and approval under a specified Himachal Pradesh land law.

Nectar Lifesciences classified results from disposed businesses and assets as discontinued operations under Ind AS 105, Asset Held for Sale and Discontinued Operations. The Capsule Business reported revenue of Rs 7.3517 crore and a loss before tax of Rs 79.72 lakh for the half year ended September 30, 2026, compared with revenue of Rs 373.9353 crore and a loss before tax of Rs 367.8766 crore in the restated prior-year period.

Conclusion

Nectar Lifesciences' Rs 26.725 crore loss on mutual fund, ETF and equity investments was a material component of its Rs 17.3475 crore consolidated pre-tax loss from continuing operations for the half year ended September 30, 2026. The filing also records Rs 879.8934 crore of investment purchases, Rs 810.6265 crore of sales and a rise in current investments to Rs 55.5126 crore.

The next disclosed items to watch are the expected sale of the remaining Garhshankar land by the end of the financial year, completion of the Rs 19.90 crore Capsule Business transaction subject to its conditions, and progress in evaluating real-estate projects. Future results may also show whether the investment portfolio produces further sale or restatement gains or losses.